The use of a stent in the treatment of lesions of the superficial femoral artery (SFA) remains controversial. Although some reports have suggested that use of a nitinol stent in conjunction with aggressive medical management is effective for long SFA lesions, few long-term, large-scale studies have been done.
he morbidity and mortality rates of peripheral arterial disease (PAD) are considered to be higher among the adult population. [1] [2] [3] [4] In the PAD population, surgical bypass tends to carry a higher risk of cardiovascular complications. 5, 6 Endovascular therapy (EVT) is a widely accepted means of treatment for PAD. 7 The development of EVT techniques and stents has enabled the treatment of longer and more complex lesions in the femoropopliteal (FP) artery. 8 According to many studies, the use of stents in the treatment of the FP artery has been found to have a high rate of initial technical success and low risk of complications. 9-11 Furthermore, according to TransAtlantic Inter-Society Consensus (TASC) II, the applicability of EVT has been widened by the effectiveness of catheter treatment.
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Stenting for lesions of the iliac artery has a high rate of initial success and long-term patency. 12 The use of stents in the treatment of lesions of the superficial femoral artery (SFA), however, remains controversial. The initial success of EVT for FP lesions was reported to be 98-100% and 81-94% for stenotic and occluded lesions, respectively. In contrast, long-term primary patency with balloon angioplasty was only 33-62%. 3 Moreover, long-term results for stent use in SFA lesions have not been favorable. Randomized control trials showed no beneficial effect for stainless-steel stents in FP lesions. 13,14 Superior patency rates compared with either plain balloon angioplasty or provisional stenting, however, have been achieved with nitinol stents. 10,15,16
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In these earlier SFA stent studies, however, the sample size was small and the follow-up period limited to a maximum of only 24 months. To compare success rates between the use of nitinol stents and conventional SFA therapy, it is necessary to analyze a larger number of cases for which long-term follow-up data are available. Therefore, we retrospectively examined data from a multicenter study on the use of nitinol stents in the treatment of lesions of the SFA.
Methods

Study Population
The J-SMART Registry is a physician-initiated, retrospective, multicenter study in Japan. We analyzed data on SFA use at a number of institutions (Sendai Kousei Hospital, Kansai Rosai Hospital, Saiseikai Yokohama-city Eastern Hospital and Kokura Memorial Hospital) between January 2004 and January 2009. Intermittent claudication or critical limb ischemia (Rutherford class 2-6) was diagnosed in all patients investigated. A total of 1,493 consecutive patients (2,037 limbs), underwent EVT for SFA. Of these, 918 patients (1,323 limbs) were excluded because of angioplasty alone, re-stenotic lesion, or use of stainless steel stent. Moreover, 143 patients (186 limbs) were also excluded due to use of Luminexx stent (Bard, Murray Hill, NJ, USA). The register contained a total of 432 patients and 528 limbs successfully treated with the S.M.A.R.T. Control™ stent (Cordis, Miami Lakes, FL, USA) for de novo lesions of the SFA, with a follow-up of at least 6 months. We divided these patients into 2 groups: a re-stenosis group and a no-restenosis group. Written informed consent was obtained from all patients. The study was approved by the ethics committees of each institution concerned and registered with the University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR), as recommended by the International Committee of Medical Journal Editors (no. UMIN000003588).
Procedure
EVT was carried out percutaneously, placing a 6-7-Fr sheath via an antegrade approach or cross-over technique. In selected cases, however, a popliteal approach was used. Prior to the intervention, 5,000 units unfractionated heparin was administered to maintain active clotting time at ≥200s. A 0.89 mm, 0.46 mm, or 0.36 mm guidewire was advanced to the target lesion with a 4-Fr multipurpose catheter and the lesion crossed. An optimally sized balloon was then dilated. Minimal balloon dilation time was 60 s. Deployment of the S.M.A.R.T. Control™ stent was carried out if there was a residual pressure gradient of >10 mmHg, residual stenosis of >30%, or flow-limiting dissection. We use the stent only for bail out in SFA lesions, because SFA stent is not approved in Japan. In such cases the stent was deployed 10 mm proximally and distally from the target lesion, and stent size was selected to be 1-2 mm larger than the diameter of the reference vessel. When multiple stents were required, the margin of the overlapping stent was <10 mm. All patients received aspirin (100 mg/day) indefinitely and cilostazol or ticlopidine (200 mg/day) for at least 4 weeks. These drugs were initiated at least 2 days prior to the procedure.
Follow-up and Outcomes
Assessment was performed at baseline, 1, 3, 6 and 12 months, and then at 12-month intervals thereafter. Factors investigated included major adverse events (death, major amputation, target lesion revascularization), staging of PAD according to the Rutherford classification, ankle brachial index (ABI) score, lesion patency as evaluated on duplex ultrasonography and stent fracture as assessed on radiography. Re-stenosis was defined as a peak systolic velocity ratio of ≥2.4 on duplex ultrasonography, which was considered indicative of a >50% narrowing. A complete absence of detectable signal was graded as complete occlusion. Radiograms were obtained in 4 planes for evaluation of stent fractures. Primary patency was 
Statistical Analysis
Statistical analysis was performed using Dr SPSS (SPSS, Chicago, IL, USA). Data are reported as mean ± SD. Continuous variables were examined using an unpaired t-test or the Mann-Whitney U-test. Categorical variables were compared Data given as mean ± SD or n (%). CTO, chronic total occlusion; TASC, Trans-Atlantic Inter-Society Consensus. 
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using the chi-squared test. Time-dependent outcomes were analyzed using the Kaplan-Meier method and compared using the log-rank test. Multiple logistic regression analysis was used to determine independent factors associated with patency. Clinically prescribed predictors (age, sex, ABI, lesion length, chronic total occlusion [CTO], stent fracture, cilostazol administration) were entered into the multivariate model. TASC II classification and the number of stents were not entered into the multivariate model because they were associated with CTO and lesion length. P<0.05 was considered statistically significant. 
Results
Baseline Characteristics
Lesion Characteristics and Intervention
The characteristics of the target lesions and intervention data are given in Table 2 . In the re-stenosis group, CTO was significantly higher (72% vs. 52%, P<0.001), lesion length significantly longer (18.6±6.9 cm vs. 14.9±8.2 cm, P<0.001) and number of stents greater than in the re-stenosis group. No statistically significant difference was observed, however, in rate of re-stenosis with below-the-knee run-offs. Fewer patients had cilostazol administration in the re-stenosis group (59% vs. 71%, P=0.024).
Follow-up Outcome and Multivariate Analysis
After the procedure, Rutherford classification improved from 3.13±1.03 to 1.33±0.76. ABI score also increased from 0.58± 0.24 to 0.84±0.19. Mean follow-up was 540±236 days. The Kaplan-Meier curves obtained (Figure 1) show that primary and secondary patency at 12, 24, 36, and 48 months was 81%, 72%, 66%, and 66%, and 91%, 89%, 87%, and 87%, respectively. Primary patency of the TASC II A, B group was good, but that of the TASC II C, D group was poor (81% vs. 51%, P<0.001; Figure 2 ). The Kaplan-Meier curves for primary patency with or without cilostazol administration are given in Figure 3 . The cilostazol group had better primary patency (71% vs. 59%, P=0.0008). Thirty-eight deaths, 9 major amputations and 50 target lesion revascularizations occurred during follow-up. There were no significant differences between the 2 groups regarding death and major amputation. Stent fracture at follow-up was more prevalent in the re-stenosis group (19% vs. 9%, P=0.007; Table 3 ). Table 4 lists the results of multivariate analysis. No cilostazol administration, female gender, younger age, and CTO were independent predictors for re-stenosis.
Discussion
Stenting for lesions of the SFA is still controversial because of the high re-stenosis rate associated with this procedure. In the present study we evaluated high-volume, long-term data from a multicenter study on use of the S.M.A.R.T. Control™ stent for treatment of SFA lesions. Primary patency was found to be 81%, 72%, 66% and 66% at 12, 24, 36, and 48 months, respectively, which was better when compared with historical data. Furthermore, 12-month primary patency in the FAST study (mean lesion length, 45 mm) was only 68%; 11 in the ASTRON study (mean lesion length, 82 mm), 66%; 16 and in the ABSOLUTE study (mean lesion length, 101 mm), 63%. 10 In contrast, the primary patency of above-knee FP bypass at 5 years has been reported to be 74-76% for vein graft and 39-54% for polytetrafluoroethylene graft. 1 The high rate of cilostazol administration (overall, 68%) observed in the present study may have contributed to the improvement in long-term results. Indeed, some randomized control trials have shown that cilostazol improved long-term results in SFA intervention. [17] [18] [19] In the present trial, cilostazol was identified as an independent factor associated with primary patency.
The results of earlier randomized trials indicate that, with balloon angioplasty, the longer the lesion, the poorer the result. The present results, obtained using multiple logistic regression, indicate that lesion length is not an independent factor associated with re-stenosis, suggesting that the effect of lesion length on long-term patency with stenting for SFA lesions is only slight.
Secondary patency was also good in the present study; and repeat revascularization can easily be performed if re-stenosis is detected early enough on non-invasive duplex scanning. Although above-knee FP bypass with vein graft is still 
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preferable in terms of long-term primary patency, the present results suggest that the S.M.A.R.T. Control™ stent offers an effective alternative to surgical revascularization in poor surgical candidates.
The present results also showed that re-stenosis tended to occur at a higher rate in female and younger patients. Exercise habits have been reported to be associated with stent fracture. 20 It has been reported that stent fracture is associated with re-stenosis. 21 This may explain the higher stent fracture rate in the re-stenosis group observed here, because younger people are more likely to be active than older people. The higher rate of re-stenosis in female patients, however, is harder to explain, because the mean stent diameter in such patients is smaller than in male patients (6.99±1.30 mm vs. 7.25±1.06 mm, P=0.016). Further study is needed to clarify this point.
The present study had several limitations: first, although high-volume and long-term data were evaluated, the study was retrospective and non-randomized; second, the possibility cannot be ruled out that the lower rate of stent fracture and higher rate of cilostazol administration observed here may have contributed to the overall better outcome achieved compared to that in previous reports; and third, no quantitative analysis of vessel diameter was performed. Despite these limitations, however, we believe that the present results indicate acceptable outcomes for use of the S.M.A.R.T. Control™ stent in the treatment of lesions of the SFA.
Conclusion
The S.M.A.R.T. Control™ stent was found to have good longterm durability in the treatment of SFA lesions. No cilostazol administration, female gender, younger age and CTO were associated with re-stenosis.
